Halper Sadeh LLC Launches Investigation into Potential Violations by AMPY, HEES, and MRNS for Shareholders

Investigation Overview

Halper Sadeh LLC, a law firm specializing in investor rights, is currently looking into potential violations of federal securities laws concerning three companies: Amplify Energy Corp. (NYSE: AMPY), HE Equipment Services, Inc. (NASDAQ: HEES), and Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS). The firm is focusing on their recent transactions and sales which may not have adequately protected shareholders’ interests.

Amplify Energy Corp. (NYSE: AMPY)

Amplify Energy is in the spotlight due to its proposed merger with Juniper Capital's Upstream Rocky Mountain Portfolio Companies. The terms of this proposed transaction involve Amplify issuing about 26.7 million shares of its common stock to Juniper. Post-transaction, it’s anticipated that Amplify's shareholders will maintain approximately 61% of the company's equity. However, concerns exist regarding whether all shareholders are being treated fairly in this deal.

If you hold shares in Amplify Energy, it is critical to learn more about your rights in this situation. Halper Sadeh LLC is prepared to explore options for you, which may include the pursuit of increased consideration or additional disclosures concerning this merger.

HE Equipment Services, Inc. (NASDAQ: HEES)

Another focus of the investigation is HE Equipment Services, which is positioned to be sold to United Rentals, Inc. for $92.00 per share, payable in cash. This sale price has raised questions regarding whether shareholders are receiving adequate value for their holdings and whether appropriate processes were followed prior to finalizing the sale.

HEES shareholders are encouraged to reach out to Halper Sadeh LLC for insights into their legal rights, as the firm seeks to ensure fair treatment and value recovery in this transaction.

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS)

The investigation also encompasses Marinus Pharmaceuticals, where a sale has been proposed to Immedica Pharma AB at a substantially lower share price of $0.55 per share. Given this significant dip in valuation, questions arise as to whether this deal is in the best interest of the shareholders, particularly in light of the company's future potential.

Those holding shares in Marinus Pharmaceuticals should be informed about their rights and the potential for the firm to advocate for a better deal or additional transparency in the sale process.

How Halper Sadeh LLC Can Help

Halper Sadeh LLC’s efforts may lead to multiple avenues for shareholder relief, including increased financial consideration, further disclosures about the transactions, or other compensatory measures. The firm operates on a contingency fee basis, meaning clients won't incur any out-of-pocket legal costs during the investigation process.

Shareholders interested in discussing their options can contact Halper Sadeh LLC directly at (212) 763-0060 or via email. The firm emphasizes that engaging with them is risk-free and may empower shareholders to make informed decisions about their investments.

Halper Sadeh LLC represents a global clientele affected by securities fraud and corporate misconduct, consistently striving for redress and reforms that benefit investors. The legal team has a proven track record of securing financial recoveries and implementing corporate governance changes that foster accountability.

In conclusion, if you are a shareholder in one of the mentioned companies, taking proactive steps now by seeking legal counsel may prove crucial to protecting your rights and interests in these potentially fraught transactions.